iOrganBio, a pioneer in intelligent cell manufacturing, announced today the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a prominent authority in stem cell biology, regenerative medicine, and translational neuroscience, whose research has significantly advanced the understanding of neurodegenerative diseases and contributed to the development of multiple therapeutic candidates.
As Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard's Department of Stem Cell and Regenerative Biology, Dr. Rubin brings extensive expertise in blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells (iPSCs), and the discovery of therapeutic candidates for disorders such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).
His appointment is expected to bolster iOrganBio's platform in neurological applications, particularly as the company focuses on FDA-aligned New Approach Methodologies (NAMs) for research and therapeutic development. iOrganBio's CellForge platform combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency, enabling scalable production for disease modeling, drug discovery, and cell therapy development.
“Dr. Rubin’s extensive academic and entrepreneurial leadership will be key to expanding iOrganBio’s platform in neurological applications,” the company stated in the announcement. The addition of Dr. Rubin underscores iOrganBio's commitment to leveraging cutting-edge science to address complex neurological diseases.
iOrganBio is transforming human cell production with CellForge, its AI-powered platform for consistent, scalable, and intelligent manufacturing of cells and organoids for in vitro modeling and cell therapies. By applying engineering precision to biology, CellForge uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At the core of the platform is iOrganBio's functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides the digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality partners need to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development.
For more information, visit iOrgan.Bio or follow the company on LinkedIn.
